In a study investigating serum concentrations of MMP-9 in SSc patients with and without PAH and in those with PAH treated or not treated with bosentan, MMP-9 levels were reported to be significantly lower in patients with PAH, and to be up-regulated following bosentan treatment [111]. Here, MMP9 is linked to systemic sclerosis.